These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22162556)

  • 1. Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer.
    Marks MA; Castle PE; Schiffman M; Gravitt PE
    J Clin Microbiol; 2012 Feb; 50(2):300-6. PubMed ID: 22162556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.
    Castle PE; Gravitt PE; Solomon D; Wheeler CM; Schiffman M
    J Clin Microbiol; 2008 Jan; 46(1):109-17. PubMed ID: 17989194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions.
    Gage JC; Schiffman M; Solomon D; Wheeler CM; Castle PE
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1668-74. PubMed ID: 20615884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptima HPV Assay versus Hybrid Capture
    Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
    J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study.
    Gravitt PE; Schiffman M; Solomon D; Wheeler CM; Castle PE
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1248-54. PubMed ID: 18483347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
    Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
    J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus genotype specificity of hybrid capture 2.
    Castle PE; Solomon D; Wheeler CM; Gravitt PE; Wacholder S; Schiffman M
    J Clin Microbiol; 2008 Aug; 46(8):2595-604. PubMed ID: 18579716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
    Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
    J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L; Oštrbenk A; Poljak M; Arbyn M
    J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.
    Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Doutre S; Michelow P; Kelly H; Didelot MN; Chikandiwa A; Sawadogo B; Delany-Moretlwe S; Meda N; Costes V; Mayaud P; Segondy M
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):162-8. PubMed ID: 25394189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
    Oštrbenk A; Xu L; Arbyn M; Poljak M
    J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
    Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C
    J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
    Fokom Domgue J; Schiffman M; Wentzensen NH; Gage JC; Castle PE; Raine-Bennett TR; Fetterman B; Lorey T; Poitras NE; Befano B; Xie Y; Miachon LS; Dean M
    J Clin Microbiol; 2017 Aug; 55(8):2348-2355. PubMed ID: 28515214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age.
    Cuschieri K; Cubie H; Graham C; Rowan J; Hardie A; Horne A; Earle CB; Bailey A; Crosbie EJ; Kitchener H
    J Clin Virol; 2014 Feb; 59(2):104-8. PubMed ID: 24380720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis of studies evaluating the performance of point-of-care tests for human papillomavirus screening.
    Kelly H; Mayaud P; Segondy M; Pant Pai N; Peeling RW
    Sex Transm Infect; 2017 Dec; 93(S4):S36-S45. PubMed ID: 29223961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.
    Gillio-Tos A; De Marco L; Carozzi FM; Del Mistro A; Girlando S; Burroni E; Frayle-Salamanca H; Giorgi Rossi P; Pierotti P; Ronco G;
    J Clin Microbiol; 2013 Sep; 51(9):2901-7. PubMed ID: 23804385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.
    Cornall AM; Poljak M; Garland SM; Phillips S; Tan JH; Machalek DA; Quinn MA; Tabrizi SN
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):545-551. PubMed ID: 27822653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
    Clad A; Reuschenbach M; Weinschenk J; Grote R; Rahmsdorf J; Freudenberg N
    J Clin Microbiol; 2011 Mar; 49(3):1071-6. PubMed ID: 21191046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.